Eintrag weiter verarbeiten
Immune Checkpoint Inhibitors: Making Immunotherapy a Reality for the Treatment of Lung Cancer
Gespeichert in:
| Zeitschriftentitel: | Cancer Immunology Research |
|---|---|
| Personen und Körperschaften: | , |
| In: | Cancer Immunology Research, 1, 2013, 2, S. 85-91 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Association for Cancer Research (AACR)
|
| Schlagwörter: |
| author_facet |
Brahmer, Julie R. Pardoll, Drew M. Brahmer, Julie R. Pardoll, Drew M. |
|---|---|
| author |
Brahmer, Julie R. Pardoll, Drew M. |
| spellingShingle |
Brahmer, Julie R. Pardoll, Drew M. Cancer Immunology Research Immune Checkpoint Inhibitors: Making Immunotherapy a Reality for the Treatment of Lung Cancer Cancer Research Immunology |
| author_sort |
brahmer, julie r. |
| spelling |
Brahmer, Julie R. Pardoll, Drew M. 2326-6066 2326-6074 American Association for Cancer Research (AACR) Cancer Research Immunology http://dx.doi.org/10.1158/2326-6066.cir-13-0078 <jats:title>Abstract</jats:title> <jats:p>Despite the limited success of immunotherapies in solid malignancy, two human cancers, melanoma and renal cancer, have, for many years, responded to systemic administration of immune-targeted biologics and showed signals of response to certain therapeutic vaccines. These findings underpinned a long-held perception that melanoma and renal cancer were uniquely “immunogenic” but that virtually all other human cancers were not and thus would not respond to immune modulation. That notion has now been shattered by the significant and durable responses in non–small cell lung cancer induced by therapeutic treatment with antibodies blocking the PD-1 checkpoint. The immunotherapy success in lung cancer thus provides a gateway to development of treatments for multiple cancer types that were previously believed not accessible to immune-based therapies. Cancer Immunol Res; 1(2); 85–91. ©2013 AACR.</jats:p> Immune Checkpoint Inhibitors: Making Immunotherapy a Reality for the Treatment of Lung Cancer Cancer Immunology Research |
| doi_str_mv |
10.1158/2326-6066.cir-13-0078 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8yMzI2LTYwNjYuY2lyLTEzLTAwNzg |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8yMzI2LTYwNjYuY2lyLTEzLTAwNzg |
| institution |
DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 |
| imprint |
American Association for Cancer Research (AACR), 2013 |
| imprint_str_mv |
American Association for Cancer Research (AACR), 2013 |
| issn |
2326-6066 2326-6074 |
| issn_str_mv |
2326-6066 2326-6074 |
| language |
English |
| mega_collection |
American Association for Cancer Research (AACR) (CrossRef) |
| match_str |
brahmer2013immunecheckpointinhibitorsmakingimmunotherapyarealityforthetreatmentoflungcancer |
| publishDateSort |
2013 |
| publisher |
American Association for Cancer Research (AACR) |
| recordtype |
ai |
| record_format |
ai |
| series |
Cancer Immunology Research |
| source_id |
49 |
| title |
Immune Checkpoint Inhibitors: Making Immunotherapy a Reality for the Treatment of Lung Cancer |
| title_unstemmed |
Immune Checkpoint Inhibitors: Making Immunotherapy a Reality for the Treatment of Lung Cancer |
| title_full |
Immune Checkpoint Inhibitors: Making Immunotherapy a Reality for the Treatment of Lung Cancer |
| title_fullStr |
Immune Checkpoint Inhibitors: Making Immunotherapy a Reality for the Treatment of Lung Cancer |
| title_full_unstemmed |
Immune Checkpoint Inhibitors: Making Immunotherapy a Reality for the Treatment of Lung Cancer |
| title_short |
Immune Checkpoint Inhibitors: Making Immunotherapy a Reality for the Treatment of Lung Cancer |
| title_sort |
immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer |
| topic |
Cancer Research Immunology |
| url |
http://dx.doi.org/10.1158/2326-6066.cir-13-0078 |
| publishDate |
2013 |
| physical |
85-91 |
| description |
<jats:title>Abstract</jats:title>
<jats:p>Despite the limited success of immunotherapies in solid malignancy, two human cancers, melanoma and renal cancer, have, for many years, responded to systemic administration of immune-targeted biologics and showed signals of response to certain therapeutic vaccines. These findings underpinned a long-held perception that melanoma and renal cancer were uniquely “immunogenic” but that virtually all other human cancers were not and thus would not respond to immune modulation. That notion has now been shattered by the significant and durable responses in non–small cell lung cancer induced by therapeutic treatment with antibodies blocking the PD-1 checkpoint. The immunotherapy success in lung cancer thus provides a gateway to development of treatments for multiple cancer types that were previously believed not accessible to immune-based therapies. Cancer Immunol Res; 1(2); 85–91. ©2013 AACR.</jats:p> |
| container_issue |
2 |
| container_start_page |
85 |
| container_title |
Cancer Immunology Research |
| container_volume |
1 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792343205704892423 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T16:47:29.493Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Immune+Checkpoint+Inhibitors%3A+Making+Immunotherapy+a+Reality+for+the+Treatment+of+Lung+Cancer&rft.date=2013-08-01&genre=article&issn=2326-6074&volume=1&issue=2&spage=85&epage=91&pages=85-91&jtitle=Cancer+Immunology+Research&atitle=Immune+Checkpoint+Inhibitors%3A+Making+Immunotherapy+a+Reality+for+the+Treatment+of+Lung+Cancer&aulast=Pardoll&aufirst=Drew+M.&rft_id=info%3Adoi%2F10.1158%2F2326-6066.cir-13-0078&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792343205704892423 |
| author | Brahmer, Julie R., Pardoll, Drew M. |
| author_facet | Brahmer, Julie R., Pardoll, Drew M., Brahmer, Julie R., Pardoll, Drew M. |
| author_sort | brahmer, julie r. |
| container_issue | 2 |
| container_start_page | 85 |
| container_title | Cancer Immunology Research |
| container_volume | 1 |
| description | <jats:title>Abstract</jats:title> <jats:p>Despite the limited success of immunotherapies in solid malignancy, two human cancers, melanoma and renal cancer, have, for many years, responded to systemic administration of immune-targeted biologics and showed signals of response to certain therapeutic vaccines. These findings underpinned a long-held perception that melanoma and renal cancer were uniquely “immunogenic” but that virtually all other human cancers were not and thus would not respond to immune modulation. That notion has now been shattered by the significant and durable responses in non–small cell lung cancer induced by therapeutic treatment with antibodies blocking the PD-1 checkpoint. The immunotherapy success in lung cancer thus provides a gateway to development of treatments for multiple cancer types that were previously believed not accessible to immune-based therapies. Cancer Immunol Res; 1(2); 85–91. ©2013 AACR.</jats:p> |
| doi_str_mv | 10.1158/2326-6066.cir-13-0078 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8yMzI2LTYwNjYuY2lyLTEzLTAwNzg |
| imprint | American Association for Cancer Research (AACR), 2013 |
| imprint_str_mv | American Association for Cancer Research (AACR), 2013 |
| institution | DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161 |
| issn | 2326-6066, 2326-6074 |
| issn_str_mv | 2326-6066, 2326-6074 |
| language | English |
| last_indexed | 2024-03-01T16:47:29.493Z |
| match_str | brahmer2013immunecheckpointinhibitorsmakingimmunotherapyarealityforthetreatmentoflungcancer |
| mega_collection | American Association for Cancer Research (AACR) (CrossRef) |
| physical | 85-91 |
| publishDate | 2013 |
| publishDateSort | 2013 |
| publisher | American Association for Cancer Research (AACR) |
| record_format | ai |
| recordtype | ai |
| series | Cancer Immunology Research |
| source_id | 49 |
| spelling | Brahmer, Julie R. Pardoll, Drew M. 2326-6066 2326-6074 American Association for Cancer Research (AACR) Cancer Research Immunology http://dx.doi.org/10.1158/2326-6066.cir-13-0078 <jats:title>Abstract</jats:title> <jats:p>Despite the limited success of immunotherapies in solid malignancy, two human cancers, melanoma and renal cancer, have, for many years, responded to systemic administration of immune-targeted biologics and showed signals of response to certain therapeutic vaccines. These findings underpinned a long-held perception that melanoma and renal cancer were uniquely “immunogenic” but that virtually all other human cancers were not and thus would not respond to immune modulation. That notion has now been shattered by the significant and durable responses in non–small cell lung cancer induced by therapeutic treatment with antibodies blocking the PD-1 checkpoint. The immunotherapy success in lung cancer thus provides a gateway to development of treatments for multiple cancer types that were previously believed not accessible to immune-based therapies. Cancer Immunol Res; 1(2); 85–91. ©2013 AACR.</jats:p> Immune Checkpoint Inhibitors: Making Immunotherapy a Reality for the Treatment of Lung Cancer Cancer Immunology Research |
| spellingShingle | Brahmer, Julie R., Pardoll, Drew M., Cancer Immunology Research, Immune Checkpoint Inhibitors: Making Immunotherapy a Reality for the Treatment of Lung Cancer, Cancer Research, Immunology |
| title | Immune Checkpoint Inhibitors: Making Immunotherapy a Reality for the Treatment of Lung Cancer |
| title_full | Immune Checkpoint Inhibitors: Making Immunotherapy a Reality for the Treatment of Lung Cancer |
| title_fullStr | Immune Checkpoint Inhibitors: Making Immunotherapy a Reality for the Treatment of Lung Cancer |
| title_full_unstemmed | Immune Checkpoint Inhibitors: Making Immunotherapy a Reality for the Treatment of Lung Cancer |
| title_short | Immune Checkpoint Inhibitors: Making Immunotherapy a Reality for the Treatment of Lung Cancer |
| title_sort | immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer |
| title_unstemmed | Immune Checkpoint Inhibitors: Making Immunotherapy a Reality for the Treatment of Lung Cancer |
| topic | Cancer Research, Immunology |
| url | http://dx.doi.org/10.1158/2326-6066.cir-13-0078 |